Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 S371C||Advanced Solid Tumor||predicted - sensitive||FGFR Inhibitor (Pan)||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, cells expressing FGFR3 S371C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).||34272467|
|FGFR3 S371C||Advanced Solid Tumor||predicted - resistant||FGFR Inhibitor (Pan)||Dovitinib||Preclinical - Cell culture||Actionable||In a preclinical study, cells expressing FGFR3 S371C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).||34272467|